Tempest Therapeutics (TPST)

• Market cap: $14.4M
• 1 day: -1.52%
• 5 days: 1.98%
• 1 month: -15.85%
• 3 months: -55.43%
• 6 months: -62.48%
• Year to date: -69.48%
• 1 year: -87.26%
• 5 years: -99.49%
• 10 years: -99.99%
• Sector: Healthcare
• Industry: Biotechnology

About: Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Employees: 4